Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Maria Shumilina"'
Autor:
Evgeniy Evdoshenko, Alexandra Stepanova, Maria Shumilina, Maria Davydovskaya, Natalia Khachanova, Nikolay Neofidov, Ivan Kalinin, Ekaterina Popova, Ekaterina Dubchenko, Natalia Pozhidaeva, Andrey Volkov, Stella Sivertseva, Anna Prilenskaya, Nadezhda Malkova, Denis Korobko, Ilona Vergunova, Sergey Shchur, Gleb Makshakov
Publikováno v:
PLoS ONE, Vol 14, Iss 5, p e0217303 (2019)
BackgroundNTZ is approved in Russia for the treatment of highly active relapsing remitting multiple sclerosis and is reimbursed via federal budget program. However, no data about NTZ treatment in Russia and the effect of federal reimbursement have be
Externí odkaz:
https://doaj.org/article/5d0bf15288324e78ba2dafd9cff30116
Autor:
Marina Kleopatra Boziki, Alexios-Fotios A. Mentis, Maria Shumilina, Gleb Makshakov, Evgeniy Evdoshenko, Nikolaos Grigoriadis
Publikováno v:
Brain Sciences, Vol 10, Iss 6, p 345 (2020)
In the frame of the coronavirus disease 2019 (COVID-19) pandemic, recent reports on SARS-CoV-2 potential neuroinvasion placed neurologists on increased alertness in order to assess early neurological manifestations and their potentially prognostic va
Externí odkaz:
https://doaj.org/article/7a732d13845e4ed19882bfdb7eb340b5
Autor:
Gleb Makshakov, Evgeniy Magonov, Natalia Totolyan, Vladimir Nazarov, Sergey Lapin, Alexandra Mazing, Elena Verbitskaya, Tatiana Trofimova, Vladimir Krasnov, Maria Shumilina, Alexander Skoromets, Evgeniy Evdoshenko
Publikováno v:
Neurology Research International, Vol 2017 (2017)
Leptomeningeal contrast enhancement (LMCE) on magnetic resonance imaging (MRI) is a newly recognized possible biomarker in multiple sclerosis (MS), associated with MS progression and cortical atrophy. In this study, we aimed to assess the prevalence
Externí odkaz:
https://doaj.org/article/2d04be3f6ba94a4596883c15b32f8ec4
Autor:
Tanuja Chitnis, Brenda Banwell, Ludwig Kappos, Douglas L Arnold, Kivilcim Gücüyener, Kumaran Deiva, Natalia Skripchenko, Li-Ying Cui, Stephane Saubadu, Wenruo Hu, Myriam Benamor, Annaig Le-Halpere, Philippe Truffinet, Marc Tardieu, Benedicte Dubois, Helene Verhelst, Veneta Bojinova-Tchamova, Jean Mah, Fang Fang, Yunpeng Hao, Li Jiang, Ling Li, Ding'An Mao, Wei Qiu, Guojun Tan, Ye Wu, Meini Zhang, Hongyu Zhou, Shuizhen Zhou, Katrin Gross-Paju, Emmanuel Cheuret, Giles Edan, Sandra Vukusic, George Chrousos, Dimitrios Zafeiriou, Anat Achiron, Adi Vaknin-Dembinsky, Bassem Yamout, Jurate Laurynaitiene, Nerija Vaiciene-Magistris, Vladimir Bojkovski, Vesna Trajkova, Sana Chaouki, Najib Kissani, Rinze Neuteboom, Filipe Palavra, Anna Belova, Alexey Boyko, Evgeny Evdoshenko, Ekaterina Kairbekova, Nadezhda Malkova, Maria Shumilina, Natalya Skripchenko, Dimitrije Nikolic, Jose Meca-Lallana, Chahnez Charfi Triki, Mhiri Chokri, Riadh Gouider, Banu Anlar, Ayse Semra Hiz, Egemen Idiman, Recai Turkoglu, Zuhal Yapici, Unsal Yilmaz, Lyudmyla Tantsura, Nataliia Voloshyna, Ming Lim, Evangeline Wassmer, Mark Cascione, Christopher LaGanke, Kevin Rathke, John Scagnelli
Publikováno v:
The Lancet Neurology, 20(12), 1001-1011. Lancet Publishing Group
Background: Therapeutic options for children with multiple sclerosis are scarce. Teriflunomide is approved in more than 80 countries for the treatment of adults with relapsing multiple sclerosis. The TERIKIDS study examined the safety and efficacy of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ccabed9102b9a00a1d52c5bf3629e63
https://pure.eur.nl/en/publications/9a1acc50-a431-44d3-9955-e7dcdc6b22c3
https://pure.eur.nl/en/publications/9a1acc50-a431-44d3-9955-e7dcdc6b22c3